A new trading day began on Tuesday, with Nurix Therapeutics Inc (NASDAQ: NRIX) stock price down -4.89% from the previous day of trading, before settling in for the closing price of $17.59. NRIX’s price has ranged from $9.22 to $29.56 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 24.84%. Meanwhile, its annual earnings per share averaged -12.18%. With a float of $73.23 million, this company’s outstanding shares have now reached $75.87 million.
Let’s determine the extent of company efficiency that accounts for 286 employees. In terms of profitability, gross margin is 77.77%, operating margin of -390.52%, and the pretax margin is -354.36%.
Nurix Therapeutics Inc (NRIX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Nurix Therapeutics Inc is 3.50%, while institutional ownership is 108.08%. The most recent insider transaction that took place on Jan 31 ’25, was worth 114,934. In this transaction Chief Legal Officer of this company sold 5,760 shares at a rate of $19.95, taking the stock ownership to the 32,538 shares. Before that another transaction happened on Jan 31 ’25, when Company’s Officer proposed sale 5,760 for $20.02, making the entire transaction worth $115,286.
Nurix Therapeutics Inc (NRIX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.76 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -12.18% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -5.35% during the next five years compared to -38.86% drop over the previous five years of trading.
Nurix Therapeutics Inc (NASDAQ: NRIX) Trading Performance Indicators
Here are Nurix Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.46. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 23.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.89, a number that is poised to hit -0.76 in the next quarter and is forecasted to reach -3.37 in one year’s time.
Technical Analysis of Nurix Therapeutics Inc (NRIX)
Looking closely at Nurix Therapeutics Inc (NASDAQ: NRIX), its last 5-days average volume was 0.66 million, which is a drop from its year-to-date volume of 0.67 million. As of the previous 9 days, the stock’s Stochastic %D was 21.81%. Additionally, its Average True Range was 1.04.
During the past 100 days, Nurix Therapeutics Inc’s (NRIX) raw stochastic average was set at 0.54%, which indicates a significant decrease from 1.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 40.96% in the past 14 days, which was lower than the 54.10% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.47, while its 200-day Moving Average is $20.85. However, in the short run, Nurix Therapeutics Inc’s stock first resistance to watch stands at $17.63. Second resistance stands at $18.52. The third major resistance level sits at $18.98. If the price goes on to break the first support level at $16.28, it is likely to go to the next support level at $15.82. Now, if the price goes above the second support level, the third support stands at $14.93.
Nurix Therapeutics Inc (NASDAQ: NRIX) Key Stats
With a market capitalization of 1.27 billion, the company has a total of 75,887K Shares Outstanding. Currently, annual sales are 54,550 K while annual income is -193,570 K. The company’s previous quarter sales were 13,280 K while its latest quarter income was -58,550 K.
